Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-26-117545·Soleus Capital Master Fund, L.P.
Schedule 13G ownership disclosure
Beta Bionics Inc
Common Stock · CUSIP: 08659B102
Event date: 2026-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Soleus Private Equity Fund II, L.P.
Shares: 1,003,961.00 · Class: 1.8%
- Soleus Private Equity GP II, LLC
Shares: 1,003,961.00 · Class: 1.8%
- Soleus PE GP II, LLC
Shares: 1,003,961.00 · Class: 1.8%
- Soleus Capital Master Fund, L.P.
Shares: 3,783,237.00 · Class: 6.8%
- Soleus Capital, LLC
Shares: 3,783,237.00 · Class: 6.8%
- Soleus Capital Group, LLC
Shares: 3,783,237.00 · Class: 6.8%
- Soleus Capital Management, L.P.
Shares: 4,787,198.00 · Class: 8.6%
- Soleus GP, LLC
Shares: 4,787,198.00 · Class: 8.6%
- Levy Guy
Shares: 4,828,619.00 · Class: 8.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-26-117545
- Form type
- SCHEDULE 13G/A
- Filer
- Soleus Capital Master Fund, L.P.
- CIK
- CIK 1812275
- Filed
- Nov 09, 2026
- Reporting period
- Sep 30, 2026
- Description
- Schedule 13G beneficial ownership